Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 8,223 shares, a decrease of 51.5% from the August 31st total of 16,949 shares. Based on an average daily volume of 27,409 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the company’s shares are short sold.
Elutia Trading Down 2.6%
NASDAQ:ELUT traded down $0.02 on Tuesday, reaching $0.79. The stock had a trading volume of 11,463 shares, compared to its average volume of 134,625. The company has a 50-day moving average of $0.87 and a 200 day moving average of $0.99. The stock has a market cap of $34.94 million, a P/E ratio of 0.83 and a beta of 0.88. Elutia has a 12-month low of $0.50 and a 12-month high of $1.39.
Elutia (NASDAQ:ELUT – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.90 million. Elutia had a negative return on equity of 407.37% and a net margin of 426.93%.
Institutional Investors Weigh In On Elutia
Analysts Set New Price Targets
Separately, Weiss Ratings lowered shares of Elutia from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Check Out Our Latest Report on Elutia
About Elutia
Elutia Inc (NASDAQ: ELUT) is a medical technology company focused on developing and commercializing biologic and drug-eluting products for regenerative medicine and implantable medical devices. Its technologies are designed to support tissue healing, improve the performance of implanted devices and address clinical needs in areas including cardiac care and orthopedics.
The company’s product portfolio has included the CanGaroo family of biologic envelopes, which are used to help manage and protect implantable electronic devices such as pacemakers and defibrillators.
See Also
- Five stocks we like better than Elutia
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
